Genetic and Pharmacologic Targeting of Eya3 in Macrophages Drives Anti-Tumor Immunity in Triple-Negative Breast Cancer
- 1University of Colorado Anschutz
Abstract
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that remains difficult to treat despite its relatively high immunogenicity, as tumors frequently evade immune destruction through mechanisms that are not yet fully understood. Here, we discover a previously unrecognized role for Eya3 within macrophages in the tumor immune microenvironment, where its expression is elevated and correlated with increased aggressiveness in TNBC. Using macrophage-targeted Eya3 knockdown and conditional knockout mouse models, we show that Eya3 depletion induces coordinated transcriptional and functional changes in macrophages, enhancing migration, antigen processing, and inflammatory signaling associated with anti-tumor immunity. Strikingly, macrophage-targeted deletion of Eya3 reprograms the immune response in TNBC, increasing CD8+ T cell infiltration, suppressing primary tumor growth, and prolonging survival. Pharmacologic inhibition of Eya1-3 tyrosine phosphatase activity with a newly derived allosteric inhibitor, LG1-34, mirrors this effect, dramatically reducing primary TNBC growth through immune-mediated mechanisms that likely act both though targeting tumor and immune cells. Importantly, TNBC patients treated with pembrolizumab exhibit high expression of Eya3 in both tumor and immune compartments, and increased macrophage specific Eya3 expression correlates with worsened response to anti-PD1 therapy. These findings identify Eya3 as a macrophage-intrinsic checkpoint on anti-tumor immunity, identifying a new potential vulnerability in TNBC.
Related
- Pharmacologic Targeting of ZNF281 Suppresses Metastatic Prostate Cancer Beyond Androgen Receptor Dependence
- Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages
- Tumor-associated macrophages beyond M1/M2 in NSCLC: spatially organized programs, therapy resistance, and translational targeting
- Single-cell RNA Sequencing Analysis Reveals That Targeting PLG–PLGRKT Signaling-mediated Pro-fibrotic Scar-associated Macrophages Ameliorates Liver Fibrosis in Biliary Atresia
- Biomimetic mycobacterial dual spatiotemporal targeting induces trained immunity for tuberculosis photothermal immunotherapy and relapse prevention
BibTeX
@misc{fields2026genetic,
title = {{Genetic and Pharmacologic Targeting of Eya3 in Macrophages Drives Anti-Tumor Immunity in Triple-Negative Breast Cancer}},
author = {K. M. Fields and G. Terue Rizzo Kodama and E. Danis and J. G. Olivas-Corral and S. R. Rosenbaum and U. Kantheti and G. Sarioglu and E. Citarella and L. Wick and K. Matlin and B. Aloe and E. G. Hawkins and A. R. Wolin and A. LaVeck and C. J. Hughes and X. Wang and R. Zhao and B. A. J. Tamburini and G. Bouchard and J. E. Slansky and H. L. Ford},
howpublished = {bioRxiv},
year = {2026},
month = jul,
doi = {10.64898/2026.07.22.739910},
url = {https://www.biorxiv.org/content/10.64898/2026.07.22.739910v2},
note = {CC BY},
}
RIS
TY - UNPB
TI - Genetic and Pharmacologic Targeting of Eya3 in Macrophages Drives Anti-Tumor Immunity in Triple-Negative Breast Cancer
AU - K. M. Fields
AU - G. Terue Rizzo Kodama
AU - E. Danis
AU - J. G. Olivas-Corral
AU - S. R. Rosenbaum
AU - U. Kantheti
AU - G. Sarioglu
AU - E. Citarella
AU - L. Wick
AU - K. Matlin
AU - B. Aloe
AU - E. G. Hawkins
AU - A. R. Wolin
AU - A. LaVeck
AU - C. J. Hughes
AU - X. Wang
AU - R. Zhao
AU - B. A. J. Tamburini
AU - G. Bouchard
AU - J. E. Slansky
AU - H. L. Ford
PY - 2026
DA - 2026/07/22
PB - bioRxiv
DO - 10.64898/2026.07.22.739910
UR - https://www.biorxiv.org/content/10.64898/2026.07.22.739910v2
AB - Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that remains difficult to treat despite its relatively high immunogenicity, as tumors frequently evade immune destruction through mechanisms that are not yet fully understood. Here, we discover a previously unrecognized role for Eya3 within macrophages in the tumor immune microenvironment, where its expression is elevated and correlated with increased aggressiveness in TNBC. Using macrophage-targeted Eya3 knockdown and conditional knockout mouse models, we show that Eya3 depletion induces coordinated transcriptional and functional changes in macrophages, enhancing migration, antigen processing, and inflammatory signaling associated with anti-tumor immunity. Strikingly, macrophage-targeted deletion of Eya3 reprograms the immune response in TNBC, increasing CD8+ T cell infiltration, suppressing primary tumor growth, and prolonging survival. Pharmacologic inhibition of Eya1-3 tyrosine phosphatase activity with a newly derived allosteric inhibitor, LG1-34, mirrors this effect, dramatically reducing primary TNBC growth through immune-mediated mechanisms that likely act both though targeting tumor and immune cells. Importantly, TNBC patients treated with pembrolizumab exhibit high expression of Eya3 in both tumor and immune compartments, and increased macrophage specific Eya3 expression correlates with worsened response to anti-PD1 therapy. These findings identify Eya3 as a macrophage-intrinsic checkpoint on anti-tumor immunity, identifying a new potential vulnerability in TNBC.
ER -